Chief Executive Officer – Richard Jones
Richard brings to Oxford Contrast a significant breadth of pharmaceutical and management experience. His career began in 1990 at Glaxo where he rapidly progressed, gaining broad commercial experience in roles in sales, marketing, finance, business analytics, sales management, country, commercial and general management.
He was responsible for a block of 15 countries as commercial director of Central and Eastern Europe (CEE) and general manager Ukraine, achieving the highest growth of any operating division globally within the Glaxo group. He has been involved in a number of blockbuster product launches; Serevent (1990), Flixotide (1992), Losec (1994), Seretide (1995) and more recently Lipitor (2006).
Richard has experience of new pharmaceutical start-ups at country level and was responsible for the integration of GlaxoWellcome and Smithkline Beecham within CEE. During his time at Pfizer he was responsible for the Lipitor National Defence Programme (UK Board report), an initiative to protect annual sales exceeding £450m.
Richard has experience of IPO, having taken Brightside through a successful AIM flotation, and the start-up of regulated entities within the financial services sector (TransSend Payments Ltd).